Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586955 | 1.00 | CXCR4 (0.43) | CXCR4OPRL1 | |
| SCHEMBL25634128 | 1.00 | CXCR4 (0.43) | CXCR4OPRL1 | |
| SCHEMBL2478196 | 1.00 | CXCR4 (0.43) | CXCR4OPRL1 | |
| SCHEMBL30586986 | 0.96 | CXCR4 (0.43) | CXCR4OPRL1 | |
| SCHEMBL2472867 | 0.96 | CXCR4 (0.43) | CXCR4OPRL1 | |
| SCHEMBL25634058 | 0.92 | CXCR4 (0.39) | CXCR4OPRL1 | |
| SCHEMBL25634473 | 0.92 | CXCR4 (0.39) | CXCR4OPRL1 | |
| SCHEMBL2475341 | 0.91 | CXCR4 (0.44) | CXCR4OPRL1 | |
| SCHEMBL8301977 | 0.91 | CXCR4 (0.44) | CXCR4OPRL1 | |
| SCHEMBL2472192 | 0.87 | CXCR4 (0.39) | CXCR4OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | claimed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | claimed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | claimed |
| WO-2023240258-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023172640-A1 | TREATMENTS FOR SINGLE-MUTANT WALDENSTRÖM'S MACROGLOBULINEMIA | X4 PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023107689-A1 | METHODS FOR TREATING PRIMARY IMMUNODEFICIENCY | X4 PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1809613-B1 | METHOD OF MAKING A 2,6-DIARYL PIPERIDINE DERIVATIVE | GENZYME CORP (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1809613-B1 | METHOD OF MAKING A 2,6-DIARYL PIPERIDINE DERIVATIVE | GENZYME CORP (US) | 2013-09-04 | — | — | EP | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | CXCR4 2190/4885OPRL1 1945/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | CXCR4 1/4885OPRL1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.